“…Despite routine application of quantitative proteomics and its integration in translational modeling in certain areas, including prediction of clearance, 2-6 DDI, 7 and effects of covariates, such as age, [8][9][10][11] disease, 12,13 ethnicity, 14,15 and genetics, 9,14,16 lack of harmonized practices in the implementation of the technique (and, hence, variability in reported abundances of the same proteins 17 ) has led to some uncertainty in the outcomes of such applications, especially when there are insufficient clinical data for verification of predictions. Some variability can be due to differences in sample matrices used (e.g., cell lysates vs. membrane fractions), whereas other differences are potentially related to the measurement technique (e.g., targeted vs. global proteomics).…”